Responsive Neurostimulation of the Thalamus Improves Seizure Control in Idiopathic Generalized Epilepsy: A Case Report
Overview
Authors
Affiliations
Background And Importance: At least 25% of patients with idiopathic generalized epilepsy do not obtain adequate seizure control with medication. This report describes the first use of responsive neurostimulation (RNS), bilaterally targeting the centromedian/ventrolateral (CM/VL) region in a patient with drug-refractory Jeavons syndrome (eyelid myoclonia with absences).
Clinical Presentation: A patient, diagnosed with eyelid myoclonia with absences (EMA) and refractory to medication, was offered RNS treatment in the CM/VL region of the thalamus. Stimulation was triggered by thalamic neural activity having morphological, spectral, and synchronous features that corresponded to 3- to 5-Hz spike-wave discharges recorded on prior scalp electroencephalography.
Conclusion: RNS decreased daily absence seizures from a mean of 60 to ≤10 and maintained the patient's level of consciousness during the occurring episodes. This therapy should be evaluated further for its potential to treat patients with pharmaco-refractory generalized epilepsy.
Bridging the Gap in FDA Approval for Pediatric Neuromodulation Devices.
Shaikhouni A, Brandon C, Criss C Children (Basel). 2025; 12(2).
PMID: 40003250 PMC: 11853837. DOI: 10.3390/children12020148.
Neurostimulation for Generalized Epilepsy: Should Therapy be Syndrome-specific?.
Warren A, Tobochnik S, Chua M, Singh H, Stamm M, Rolston J Neurosurg Clin N Am. 2023; 35(1):27-48.
PMID: 38000840 PMC: 10676463. DOI: 10.1016/j.nec.2023.08.001.
The Utility of Responsive Neurostimulation for the Treatment of Pediatric Drug-Resistant Epilepsy.
Piazza M, Varga G, Welch W, Abel T Brain Sci. 2023; 13(10).
PMID: 37891823 PMC: 10605851. DOI: 10.3390/brainsci13101455.
Remore L, Rifi Z, Nariai H, Eliashiv D, Fallah A, Edmonds B Ther Adv Neurol Disord. 2023; 16:17562864231202064.
PMID: 37822361 PMC: 10563482. DOI: 10.1177/17562864231202064.
Fields M, Eka O, Schreckinger C, Dugan P, Asaad W, Blum A Front Neurol. 2023; 14:1202631.
PMID: 37745648 PMC: 10516547. DOI: 10.3389/fneur.2023.1202631.